Abstract: A skin care composition, including: (a) a lipid-regulating agent; (b) a skin barrier repairing agent; (c) a bioflavonoid; (d) an antimicrobial lipid; (e) a UV protectant/photoprotective agent; and (f) wherein the composition is formulated to restore the skin barrier, regulate sebum production, and enhance sebum quality in blemish-prone skin.

Abstract: Provided is a collaborative care method for scalp hair follicles and strands, which includes using collaboratively rinse shampoo and conditioner. The shampoo includes a mild surfactant, a hair follicle support complex, a cationic conditioning polymer, and a microbiome regulator. The conditioner includes amino functional silicone oil, a fatty alcohol system, a cationic conditioning system, and a hair follicle support enhancing ingredients. The method utilizes a synergistic mechanism of cation deposition and carrier, lipid surfactant composite deposition, and geometric retention at hair follicle openings. Shampoo and conditioner form a synergistic method of continuous use.

Abstract: The disclosure generally concerns antimicrobial compositions, specifically the disclosure concerns combinations that have antimicrobial synergistic activity against various microorganisms, more specifically compositions of at least one 4-pyrone derivative and one or more additional materials, in particular combinations of maltol with trans-cinnamaldehyde, extracts or oil of plants from the genus Cinnamomum.

Abstract: The present invention relates to an injectable composition, a pharmaceutical formulation comprising the same, and a method for preparing the same The injectable composition according to the present invention comprises: azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone citrate as active ingredient; and SBE-?-CD.

Abstract: The present invention relates to a macrolide for use in a method of preventing or treating an immunological disease or disorder, preferably a transplant rejection, comprising administering said macrolide at least twice daily, wherein said administering at least twice daily comprises administering a first dose at a first time point and a second dose at a second time point, wherein said second time point is at a time point in a range of from about 1 h to about 7 h, preferably of from about 2 h to about 5 h, more preferably of from about 2.5 h to about 3.5 h, even more preferably about 3 h, after said first time point. The present invention also relates to tacrolimus mucoadhesive films suitable for buccal administration.

Abstract: The invention, provides a method and a device for delivery of foam to a target site of a respiratory system of a subject.

Abstract: The present disclosure provides pharmaceutical compositions for use in delivering therapeutics, such as vaccines or biologic material, to the nasal cavity or the deep lungs. In particular, the pharmaceutical compositions may preferentially deposit on the lower or middle turbinate region and the nasopharynx region of the nasal cavity. In other aspects the pharmaceutical compositions may be used to generate powders that penetrate the deep lungs. Also, provided herein are methods of preferential delivery to these regions.

Abstract: Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent.

Abstract: A nanopreparation loaded with trabectedin and paclitaxel is provided. The nanopreparation loaded with trabectedin and paclitaxel includes a non-targeted drug-loaded micelle loaded with paclitaxel and a first targeting group linked to a first micelle carrier, where the non-targeted drug-loaded micelle has a first shell-core structure, and the first micelle carrier is prepared from poly(?-caprolactone)-poly(2-ethyl-2-oxazoline) (PCL-PEOz), where a hydrophobic block of PCL and paclitaxel jointly form a core of the first shell-core structure, and a hydrophilic block of PEOz forms a shell of the first shell-core structure; and the first targeting group is linked via an amide bond formed between —NH2 on a surface of the first targeting group and —COOH at a terminus of the PEOz on a surface of the shell.

Abstract: In certain embodiments, the present invention relates to biodegradable microparticles for sustained release drug-delivery, comprising an active agent and a covalently and three dimensionally crosslinked polymer matrix, methods for preparing and use thereof. Furthermore, the present invention relates in certain embodiments to a pharmaceutically acceptable, sustained release, biodegradable drug-delivery’system, comprising biodegradable microparticles for sustained release drug-delivery, particularly for coating a medical implant or for use as a medical implant, and methods of manufacturing it. The present invention also relates in certain embodiments to corresponding methods of treatment, methods for controlling active agent release and uses of the biodegradable microparticles for sustained release drug-delivery.

Abstract: A process for the production of a chimeric antibody, comprising: a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first part which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein; b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule; c) transforming an immortalised mammalian cell line with the or both prepared vectors; and d) culturing said transformed cell line to produce the chimeric antibody; chimeric antibodies produced by this process; and plasmids and transformed cell lines used in the process.

Abstract: The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or (Lyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacyrlamide to a cysteine or other sulfur group.

Abstract: The present invention relates to a method of preparing an aqueous dispersion of nanoparticles of a hydrophobic active pharmaceutical ingredient (API). The present invention also relates to a plurality of nanoparticles produced by such method. Furthermore, the present invention relates to uses of such nanoparticles.

Abstract: Beta-hydroxybutyrate compositions for administering ketone bodies to a subject include a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate enriched with R-beta-hydroxybutyrate so as to contain more than 50% and less than 100% by enantiomeric equivalents of R-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of S-beta-hydroxybutyrate. Non-racemic mixtures of beta-hydroxybutyrate include one or more R-beta-hydroxybutyrate salts, one or more S-beta-hydroxybutyrate salts, one or more R-beta-hydroxybutyrate esters, one or more S-beta-hydroxybutyrate esters, R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and combinations thereof.

Abstract: Methods and compositions for treating rheumatoid arthritis are provided which include administering an effective amount of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject in need thereof. In embodiments, compositions for treating rheumatoid arthritis that include(S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof are administered to a subject in need thereof.

Abstract: The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the treatment and management of acne-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) pantothenic acid; (b) folic acid; (c) myo-inositol; (d) methylsulfonylmethane (MSM); (e) holy basil extract; (f) optionally, turmeric root extract; (g) barberry root extract; (h) L-theanine; and (i) milk thistle extract.

Abstract: The present disclosure describes methods comprising administering N-acetylcysteine (NAC) or a pharmaceutically-acceptable salt or congener thereof. The disclosed methods can be used to treat a brain disorder.

Abstract: Provided is a fenofibrate-based oily formulation, an oral medicine, and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The fenofibrate-based oily formulation includes components of fenofibrate, an oily solvent, and a surfactant. A preparation method of the fenofibrate-based oily formulation is further provided, including the following steps: mixing the components, and then heating and stirring an obtained mixed product to obtain a clear oil solution as the fenofibrate-based oily formulation. The fenofibrate-based oily formulation enhances oral bioavailability of fenofibrate and ensures that oral absorption of the fenofibrate remains unaffected by dietary conditions.

Abstract: The invention relates to allicin and related compounds for use in the prevention or treatment of epilepsy.

Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.